AZ licensed the drug from Ionis six years ago, and was still firmly behind the programme when it reported results of the phase 2b ETESIAN trial earlier this year, which revealed a 73% reduction in ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

MD, PhD, Founder, Chairman and Chief Executive Officer of Ionis Pharmaceuticals Akcea Therapeutics, 22 Boston Wharf Rd, 9th Fl, Boston, Massachusetts 02210, United States. It is a well-known fact ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core ...